Search details
1.
Integrative clinical genomics of advanced prostate cancer.
Cell
; 161(5): 1215-1228, 2015 May 21.
Article
in English
| MEDLINE | ID: mdl-26000489
2.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature
; 595(7867): 432-437, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34135506
3.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Article
in English
| MEDLINE | ID: mdl-35179323
4.
Integrative Clinical Genomics of Advanced Prostate Cancer.
Cell
; 162(2): 454, 2015 Jul 16.
Article
in English
| MEDLINE | ID: mdl-28843286
5.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
Prostate
; 84(3): 292-302, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37964482
6.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Oncologist
; 29(3): 235-243, 2024 Mar 04.
Article
in English
| MEDLINE | ID: mdl-37812679
7.
Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.
Curr Treat Options Oncol
; 25(3): 293-312, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38291265
8.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 383(24): 2345-2357, 2020 12 10.
Article
in English
| MEDLINE | ID: mdl-32955174
9.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(23): 2197-2206, 2020 06 04.
Article
in English
| MEDLINE | ID: mdl-32469184
10.
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(22): 2091-2102, 2020 05 28.
Article
in English
| MEDLINE | ID: mdl-32343890
11.
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
J Urol
; 209(3): 532-539, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36756959
12.
Pandemic beyond the virus: maternal COVID-related postnatal stress is associated with infant temperament.
Pediatr Res
; 93(1): 253-259, 2023 01.
Article
in English
| MEDLINE | ID: mdl-35444294
13.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Future Oncol
; 19(29): 1953-1960, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37585665
14.
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(3): 393-405, 2022 03.
Article
in English
| MEDLINE | ID: mdl-35157830
15.
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Prostate
; 82(12): 1176-1185, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35538398
16.
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Future Oncol
; 18(21): 2585-2597, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35656777
17.
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Future Oncol
; 18(35): 3867-3874, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36226865
18.
Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
Jpn J Clin Oncol
; 52(5): 441-448, 2022 May 05.
Article
in English
| MEDLINE | ID: mdl-35229141
19.
Vertical Transmission and Neonatal Outcomes Following Maternal SARS-CoV-2 Infection During Pregnancy.
Clin Obstet Gynecol
; 65(1): 195-202, 2022 03 01.
Article
in English
| MEDLINE | ID: mdl-35045041
20.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33721560